Harvard Bioscience, Inc.
HBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $91,865 | $226,947 | $114,714 | $284,418 |
| - Cash | $4,108 | $4,283 | $4,508 | $7,821 |
| + Debt | $44,495 | $42,773 | $54,241 | $56,960 |
| Enterprise Value | $132,252 | $265,437 | $164,447 | $333,557 |
| Revenue | $94,135 | $112,250 | $113,335 | $118,904 |
| % Growth | -16.1% | -1% | -4.7% | – |
| Gross Profit | $54,766 | $66,071 | $60,819 | $67,652 |
| % Margin | 58.2% | 58.9% | 53.7% | 56.9% |
| EBITDA | -$1,474 | $8,033 | $944 | $9,021 |
| % Margin | -1.6% | 7.2% | 0.8% | 7.6% |
| Net Income | -$12,405 | -$3,415 | -$9,516 | -$288 |
| % Margin | -13.2% | -3% | -8.4% | -0.2% |
| EPS Diluted | -0.28 | -0.081 | -0.23 | -0.007 |
| % Growth | -247.8% | 65% | -3,139.4% | – |
| Operating Cash Flow | $1,440 | $14,028 | $1,152 | $1,262 |
| Capital Expenditures | -$3,263 | -$2,311 | -$1,590 | -$1,345 |
| Free Cash Flow | -$1,823 | $11,717 | -$438 | -$83 |